Drospirenone/E2 reduces BP in postmenopausal women with hypertension

Article

Hormonal therapy with drospirenone plus estradiol (E?) lowers blood pressure and spares potassium in postmenopausal women on hydrochlorothiazide (HCTZ). So say results of a small randomized, placebo-controlled trial presented at the 17th annual NAMS meeting.

Hormonal therapy with drospirenone plus estradiol (E2) lowers blood pressure and spares potassium in postmenopausal women on hydrochlorothiazide (HCTZ). So say results of a small randomized, placebo-controlled trial presented at the 17th annual NAMS meeting.

Thirty-six women taking 25 mg/d of HCTZ for stage 1 hypertension were included in the crossover study, conducted by investigators from the University of Miami and Berlex Laboratories. The participants were randomized to 3 mg drospirenone/E2 or placebo for 4 weeks and then crossed over for another 4 weeks.

Drospirenone/E2 reduced systolic and diastolic blood pressure by 7.2 mm Hg and 4.5 mm Hg, respectively, and potassium was 0.2 mEq/L higher than with placebo. The only significant adverse effects of the hormonal therapy were vaginal bleeding and breast tenderness.

Related Videos
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Fertility counseling for oncology patients | Image Credit: allhealthtv.com
Learning what women prefer in STI preventive care
Related Content
© 2024 MJH Life Sciences

All rights reserved.